Hormonal
Obesity-induced adipose tissue dysfunction and systemic insulin resistance drive the development of MAFLD/NASH, which in turn exacerbates cardiovascular disease risk through the release of pro-atherogenic, pro-coagulant, and pro-inflammatory mediators from the liver.
If you have fatty liver disease (MAFLD/NASH), your liver is actively sending chemical signals that increase your risk of heart disease and stroke, independent of your weight. Managing liver health through weight loss and metabolic control is critical for cardiovascular protection, not just liver protection.
MAFLD is associated to both peripheral and hepatic insulin resistance... NASH exacerbates hepatic and peripheral insulin resistance, inducing atherogenic dyslipidemia and releasing pro-inflammatory factors, vasoactive factors, and thrombogenic molecules, which are involved with hypertension and the development of CVD...
Why this rating
The paper is a review citing multiple meta-analyses and large-scale observational studies, though it lacks primary interventional data.
Source
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas et al. · International Journal of Molecular Sciences · 2021
DOI 10.3390/ijms222111629
More from this paper
- Obesity causes structural and functional cardiac alterations, including left ventricular hypertrophy, diastolic dysfunction, and atrial fibrillation, primarily through increased blood volume, cardiac output, and neuro-hormonal activation (RAAS).Good
- Insulin resistance is a major cardiovascular risk factor in subjects without diabetes and serves as a key link between MAFLD/NASH and cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →